Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionBlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I
Latest Disclosed Ownership28 shares
Latest Disclosed Value $ 12,465
BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I reports 61.11% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On August 28, 2025 - BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I filed a NPORT-P form disclosing ownership of 28 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $12,466 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 72 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -61.11% during the quarter. The current value of the position is $12,048 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP Vertex Pharmaceuticals EC US92532F1003 28 -44 -61.11 12 -64.71 0.0082
2025-05-27 2025-03-31 NP Vertex Pharmaceuticals EC US92532F1003 72 -44 -37.93 35 -26.09 0.0233
2025-02-27 2024-12-31 NP Vertex Pharmaceuticals EC US92532F1003 116 47 68.12 47 43.75 0.0289
2024-08-27 2024-06-30 NP Vertex Pharmaceuticals EC US92532F1003 69 -772 -91.80 32 -90.88 0.0196
2024-05-28 2024-03-31 NP Vertex Pharmaceuticals EC US92532F1003 841 480 132.96 352 140.41 0.2053
2024-02-27 2023-12-31 NP Vertex Pharmaceuticals EC US92532F1003 361 -349 -49.15 147 -40.65 0.0881
2023-11-22 2023-09-30 NP Vertex Pharmaceuticals EC US92532F1003 710 306 75.74 247 73.24 0.1485
2023-08-25 2023-06-30 NP Vertex Pharmaceuticals EC US92532F1003 404 -388 -48.99 142 -42.97 0.0832
2023-05-26 2023-03-31 NP Vertex Pharmaceuticals EC US92532F1003 792 24 3.12 250 12.67 0.1474
2023-02-24 2022-12-31 NP Vertex Pharmaceuticals EC US92532F1003 768 -179 -18.90 222 -19.34 0.1274
2022-11-28 2022-09-30 NP Vertex Pharmaceuticals EC US92532F1003 947 -76 -7.43 274 -4.86 0.1610
2022-08-26 2022-06-30 NP Vertex Pharmaceuticals EC US92532F1003 1,023 -220 -17.70 288 -11.11 0.1618
2022-05-25 2022-03-31 NP Vertex Pharmaceuticals EC US92532F1003 1,243 343 38.11 324 64.47 0.1637
2022-02-25 2021-12-31 NP Vertex Pharmaceuticals EC US92532F1003 900 128 16.58 198 40.71 0.0920
2021-11-26 2021-09-30 NP Vertex Pharmaceuticals EC US92532F1003 772 319 70.42 140 53.85 0.0641
2021-08-24 2021-06-30 NP Vertex Pharmaceuticals EC US92532F1003 453 82 22.10 91 15.19 0.0415
2021-05-25 2021-03-31 NP Vertex Pharmaceuticals EC US92532F1003 371 -294 -44.21 80 -49.68 0.0364
2021-02-24 2020-12-31 NP Vertex Pharmaceuticals EC US92532F1003 665 6 0.91 157 -12.29 0.0703
2020-11-24 2020-09-30 NP Vertex Pharmaceuticals EC US92532F1003 659 -219 -24.94 179 -29.53 0.0848
2020-08-24 2020-06-30 NP Vertex Pharmaceuticals EC US92532F1003 878 -652 -42.61 255 -30.22 0.1221
2020-05-26 2020-03-31 NP Vertex Pharmaceuticals EC US92532F1003 1,530 357 30.43 364 42.19 0.1793
2020-02-25 2019-12-31 NP Vertex Pharmaceuticals EC 92532F100 1,173 -998 -45.97 257 -30.25 0.1087
2019-11-25 2019-09-30 NP Vertex Pharmaceuticals EC US92532F1003 2,171 2,171 368 0.1565
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.